NCT01134523

Regimens Comparison for Breast Cancers of Positive Lymph Nodes

Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes

Detailed description

EC-T regimen: epirubicin 90mg/m2 day1, CTX 600mg/m2, day 1, 21 days per cycle \*4cycle. followed by paclitaxel 175mg/m2,d1,21days per cycle, 4 cycle. ET regimen: epirubicin 75mg/m2 day1,paclitaxel 175mg/m2,d2,21days per cycle, 6 cycle

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Epirubicin, CTX, Paclitaxel	Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
DRUG	Epirubicin, Paclitaxel	Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.

Timeline

• Start date: 2010-05-01
• Primary completion: 2018-05-01
• Completion: 2020-05-01
• First posted: 2010-06-02
• Last updated: 2013-03-15

Locations

1 site across 1 country: China